Theravance initiates Phase 2b study with TD-4208 Theravance announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist, discovered using Theravance's multivalent approach to drug design. This compound is under development by Theravance for the treatment of chronic obstructive pulmonary disease, or COPD.
Theravance sees results from Salford COPD lung study in 2016 "Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.